-transparent.png){kind=logo}
In patients with Parkinson' disease and dopaminergic psychosis, clozapine treatment is recommended as the drug is free from extrapyramidal side effects and does not worsen motor symptoms of the underlying disease. The use of clozapine, however, is limited due to its hematotoxic side effects. For treatment of clozapine-induced agranulocytosis, granulocyte colony-stimulating factors (G-CSF) are recommended. We report the case of a 72-years-old male patient with clozapine-induced agranulocytosis and thrombopenia. Neutropenia was successfully treated with G-CSF, but thrombopenia persisted and resolved spontaneously after 14 days. Bone marrow toxicity of clozapine is not restricted to white cell maturation, but may also impair thrombocytopoesis.
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
May 2006,
Psychiatrische Praxis,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
January 1963,
Nouvelle revue francaise d'hematologie,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
January 1994,
Harefuah,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
November 2020,
Annals of hematology,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
January 1987,
Blut,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
December 1996,
The Australian and New Zealand journal of psychiatry,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
January 2013,
General hospital psychiatry,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
January 2004,
Clinical neuropharmacology,
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
June 2006,
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999),
J Rudolf, and
M Grond, and
M Neveling, and
W D Heiss
October 1991,
Clinical pharmacy,
